Clinical trial
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar…
NCT00436332 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00436332 |
|---|---|
| Title | S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma |
| Official title | A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, erlotinib hydrochloride |
| Enrollment | 84 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 20, 2019 |
| Completion | Aug 20, 2019 |
| First posted | Feb 19, 2007 |
| Last update posted | Apr 2, 2020 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: